Literature DB >> 6091638

Functional GIP receptors in a hamster pancreatic beta cell line, In 111: specific binding and biological effects.

B Amiranoff, N Vauclin-Jacques, M Laburthe.   

Abstract

Specific binding sites for GIP have been characterized in a insulin-secreting pancreatic tumor cell line, In 111. The specific binding of 125I-GIP is time, temperature and cells concentration dependent. Under steady state conditions (2 hours at 13 degrees C) specific binding of 125I-GIP (0.3 nM) is competitively inhibited by increasing concentrations of native GIP from 10(-10) to 10(-6) M. Scatchard analysis reveals the presence of two types of sites: a high affinity (KD = 7 nM)/low capacity (3000 sites/cell) site and a low affinity (KD = 800 nM)/high capacity (150,000 sites/cell) site. No other peptide structurally related or not to GIP, interacts with GIP receptors. GIP (10(-10) to 10(-6) M) is able to potently stimulate insulin release in In 111 cells. At 37 degrees C, the stimulation is rapid and reaches a maximum from 30 minutes of incubation. Half-maximal stimulation is elicited by 10 nM GIP and maximal effect reaches 3 times the basal level of insulin release. Concomitantly, GIP (10(-10) - 10(-6) M) increases the basal cyclic AMP level in the cells. Half-maximal stimulation is observed in the presence of 30 nM GIP, maximal stimulation induced by 10(-6) M peptide increases up to 4 times the basal cyclic AMP production. In conclusion, our data provide the first description of a functional GIP receptor in an insulin-secreting pancreatic beta cell.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6091638     DOI: 10.1016/0006-291x(84)90281-x

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

Review 1.  Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.

Authors:  Marzieh Salehi; Benedikt A Aulinger; David A D'Alessio
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

2.  The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion.

Authors:  I R Jones; D R Owens; A J Moody; S D Luzio; T Morris; T M Hayes
Journal:  Diabetologia       Date:  1987-09       Impact factor: 10.122

Review 3.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.